CD39, also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase­1) and NTPDase-1, is a two pass, type II transmembrane protein with an extracellular active site that hydrolyzes extracellular ATP and ADP to AMP. CD39 can hydrolyze ATP and ADP equally well. CD39 was originally discovered as a B lymphocyte cell surface marker, but it is also expressed on the surface of natural killer (NK) cells, T cells, neuron tissues and some endothelial cells. CD39 is involved in the processes of thromboregulation and vascular inflammation. In the central nervous system, CD39 hydrolyzes extracellular ATP and other nucleotides to regulate purinergic signaling and transmission. It is also implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. The mutations in the CD39 gene cause SPG64 (spastic paraplegia 64), an autosomal recessive neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. The administration of soluble ecto-enzyme of ENTPD1 may have therapeutic potential for treating some vascular and transplantation­associated diseases. Inhibition of this protein's activity may confer anticancer benefits.

CD39, also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase­1) and NTPDase-1, is a two pass, type II transmembrane protein with an extracellular active site that hydrolyzes extracellular ATP and ADP to AMP. CD39 can hydrolyze ATP and ADP equally well. CD39 was originally discovered as a B lymphocyte cell surface marker, but it is also expressed on the surface of natural killer (NK) cells, T cells, neuron tissues and some endothelial cells. CD39 is involved in the processes of thromboregulation and vascular inflammation. In the central nervous system, CD39 hydrolyzes extracellular ATP and other nucleotides to regulate purinergic signaling and transmission. It is also implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. The mutations in the CD39 gene cause SPG64 (spastic paraplegia 64), an autosomal recessive neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. The administration of soluble ecto-enzyme of ENTPD1 may have therapeutic potential for treating some vascular and transplantation­associated diseases. Inhibition of this protein's activity may confer anticancer benefits.

 

Product Details

 

Gene Symbol: CD39; ENTPD1; SPG64; ATPDase; NTPDase-1; Ecto-ATPase 1; Ecto-ATPDase 1

 

NCBI Gene ID: 953

 

Uniprot Entry: P49961

 

Construct Details: Full length human CD39 gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and a selection marker, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles.

 

Vector Type: pLTC or pLTC-IRES-Marker (lentiviral expression vector containing a heterologous CMV promoter, see the vector map above)

 

Formulation: Supplied with 10 μg of endotoxin-free plasmid DNA at 200 ng/μl in sterile TE buffer (pH8.0)

 

Gene Insert Size: 1533 (bp)

 

Gene Insert Sequence:  

ATGGAAGATACAAAGGAGTCTAACGTGAAGACATTTTGCTCCAAGAATATCCTAGCCATCCTTGGCTTCT

CCTCTATCATAGCTGTGATAGCTTTGCTTGCTGTGGGGTTGACCCAGAACAAAGCATTGCCAGAAAACGT

TAAGTATGGGATTGTGCTGGATGCGGGTTCTTCTCACACAAGTTTATACATCTATAAGTGGCCAGCAGAA

AAGGAGAATGACACAGGCGTGGTGCATCAAGTAGAAGAATGCAGGGTTAAAGGTCCTGGAATCTCAAAAT

TTGTTCAGAAAGTAAATGAAATAGGCATTTACCTGACTGATTGCATGGAAAGAGCTAGGGAAGTGATTCC

AAGGTCCCAGCACCAAGAGACACCCGTTTACCTGGGAGCCACGGCAGGCATGCGGTTGCTCAGGATGGAA

AGTGAAGAGTTGGCAGACAGGGTTCTGGATGTGGTGGAGAGGAGCCTCAGCAACTACCCCTTTGACTTCC

AGGGTGCCAGGATCATTACTGGCCAAGAGGAAGGTGCCTATGGCTGGATTACTATCAACTATCTGCTGGG

CAAATTCAGTCAGAAAACAAGGTGGTTCAGCATAGTCCCATATGAAACCAATAATCAGGAAACCTTTGGA

GCTTTGGACCTTGGGGGAGCCTCTACACAAGTCACTTTTGTACCCCAAAACCAGACTATCGAGTCCCCAG

ATAATGCTCTGCAATTTCGCCTCTATGGCAAGGACTACAATGTCTACACACATAGCTTCTTGTGCTATGG

GAAGGATCAGGCACTCTGGCAGAAACTGGCCAAGGACATTCAGGTTGCAAGTAATGAAATTCTCAGGGAC

CCATGCTTTCATCCTGGATATAAGAAGGTAGTGAACGTAAGTGACCTTTACAAGACCCCCTGCACCAAGA

GATTTGAGATGACTCTTCCATTCCAGCAGTTTGAAATCCAGGGTATTGGAAACTATCAACAATGCCATCA

AAGCATCCTGGAGCTCTTCAACACCAGTTACTGCCCTTACTCCCAGTGTGCCTTCAATGGGATTTTCTTG

CCACCACTCCAGGGGGATTTTGGGGCATTTTCAGCTTTTTACTTTGTGATGAAGTTTTTAAACTTGACAT

CAGAGAAAGTCTCTCAGGAAAAGGTGACTGAGATGATGAAAAAGTTCTGTGCTCAGCCTTGGGAGGAGAT

AAAAACATCTTACGCTGGAGTAAAGGAGAAGTACCTGAGTGAATACTGCTTTTCTGGTACCTACATTCTC

TCCCTCCTTCTGCAAGGCTATCATTTCACAGCTGATTCCTGGGAGCACATCCATTTCATTGGCAAGATCC

AGGGCAGCGACGCCGGCTGGACTTTGGGCTACATGCTGAACCTGACCAACATGATCCCAGCTGAGCAACC

ATTGTCCACACCTCTCTCCCACTCCACCTATGTCTTCCTCATGGTTCTATTCTCCCTGGTCCTTTTCACA

GTGGCCATCATAGGCTTGCTTATCTTTCACAAGCCTTCATATTTCTGGAAAGATATGGTATAG

 

 

Primers: Gene insert coding sequence can be confirmed by following primers:

(a) forward (or 5'-end) primer: 5’-CAAATGGGCGGTAGGCGTG-3’;

(b) reverse (or 3'-end) primer: 5’-CCAGGTTTCCGGGCCCTCAC-3’

 

 

Note: The sequence may vary due to the naturally occurring variants or mutations, such as single nucleotide polymorphism, or the artifact during PCR amplification.  High fidelity PCR systems should always be used. 

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. Int. J. Cancer 29:373 (1982).

2. J. Immunol. 146:2235 (1991).

3. J. Biol. Chem. 271:33116 (1996)

4. Semin. Thromb. Hemost. 31:234 (2005)

5. Science 343:506 (2014)

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: LTP2155-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.